About Theralase Technologies

Theralase Technologies Inc., a biopharmaceutical company, focuses on the design, development, manufacturing, and sale of patented laser technology platforms used in a range of bio-stimulative and bio-destructive clinical applications in patients. Divisions The company operates through two divisions, Photo Dynamic Therapy (PDT) and Therapeutic Laser Technology (TLT). PDT This division develops patented and patent pending drugs, called photo dynamic compounds (PDCs) and activates them with proprietary and patent pending laser technology to destroy primarily targeted cancers. This division focuses on the discovery of small, light-activated molecules; and the development of laser systems that target and destroy cancer cells, control bacterial infections, and promote microbial sterilization. PDCs are drugs that are cytotoxic (cell killing) when exposed to light at specific wavelengths and power levels. The company’s PDCs could be activated by a range of laser wavelengths and function regardless of the oxygenation level present in the tissue under treatment, an advantageous feature when dealing with cancerous tissue and certain bacteria that thrive in low oxygenated tissues. The company has partnered with the primary Princess Margaret Cancer Centre in Toronto, Canada; and is designing a Phase II clinical study of non-muscle invasive bladder cancer (NMIBC) using its primary PDC. The company’s TLD-1433 PDC has proven to be toxic to bladder cancer cells when activated by light, producing a 100% kill rate at very low concentrations. The company’s Anti-Cancer technology has been successfully evaluated in a Phase 1b Clinical Study for NMIBC. The company has launched Phase II NMIBC Clinical Study, with five patients treated at the Princess Margaret Cancer Centre in Toronto, Canada. TLT This division designs, develops, manufactures and markets patented and proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration for the healing of chronic knee pain. The company develops products both internally and using the assistance of specialist external resources. Successful financing enables the commercialization of the company’s product offerings, which is further supported through the company’s established network of direct sales and indirect distribution networks. The company’s patented cool laser therapy devices are clinically indicated and cleared by worldwide regulatory bodies for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation, and acceleration of tissue healing for various nerve, muscle, and joint conditions. Products The company’s products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of tissue healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. Customers The company sells its products to healthcare practitioners. Significant Events In August 2020, the company had executed a sponsored research agreement (SRA) with the University of Manitoba (UM) Medical Microbiology department to commence development of a coronavirus vaccine and therapy utilizing the company’s patented and proprietary PDCs. According to the SRA, UM would conduct experiments in conjunction with the company for the research and development of a coronavirus vaccine and therapeutic to be further evaluated in animal then human clinical testing in 2021. History Theralase Technologies Inc. was founded in 1994.